UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 55

Sortiert nach

Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson’s Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study

Neurology and therapy, 2023-12, Vol.12 (6), p.1937-1958

2023

Volltextzugriff (PDF)

New applications of disease genetics and pharmacogenetics to drug development

Current opinion in pharmacology, 2014-02, Vol.14, p.81-89

2014

Volltextzugriff (PDF)

Advancing combination therapy for Alzheimer's disease

Alzheimer's & dementia : translational research & clinical interventions, 2020, Vol.6 (1), p.e12073-n/a

2020

Volltextzugriff (PDF)

Correction: Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson’s Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study

Neurology and therapy, 2023-12, Vol.12 (6), p.1959-1960

2023

Volltextzugriff (PDF)

0895 Pharmacokinetics of pitolisant in breast milk and serum of healthy lactating women

Sleep (New York, N.Y.), 2023-05, Vol.46 (Supplement_1), p.A394-A395

2023

Volltextzugriff (PDF)

Rapid Eye Movement Sleep Behavior Disorder

Chest, 2017-09, Vol.152 (3), p.650-662

2017

Volltextzugriff (PDF)

Rapid Eye Movement Sleep Behavior Disorder: A Review of the Literature and Update on Current Concepts

Chest, 2017-09, Vol.152 (3), p.650-662

2017

Volltextzugriff (PDF)

Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial

Lancet neurology, 2022-12, Vol.21 (12), p.1099-1109

2022

Volltextzugriff (PDF)

Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial

Lancet neurology, 2021-03, Vol.20 (3), p.182-192

2021

Volltextzugriff (PDF)

Portable Monitoring and the Diagnosis of Obstructive Sleep Apnea

Indian journal of sleep medicine, 2015, Vol.10 (2), p.59-63

Budur, Kumar

2015

Volltextzugriff (PDF)

Tilavonemab in early Alzheimer’s disease: results from a phase 2, randomized, double-blind study

Brain (London, England : 1878), 2023-06, Vol.146 (6), p.2275-2284

2023

Volltextzugriff (PDF)

Advances in treating insomnia

Cleveland Clinic journal of medicine, 2007-04, Vol.74 (4), p.251-252

2007

Volltextzugriff (PDF)

Innovative Approaches for Slowing Disease Progression in Parkinson's Disease: Takeaways from the 14th Annual International Society for Central Nervous System Clinical Trials and Methodology Scientific Meeting

Innovations in clinical neuroscience, 2020-01, Vol.17 (1-3), p.14-19

2020

Volltextzugriff (PDF)

Efficacy and safety of sublingual ramelteon as an adjunctive therapy in the maintenance treatment of bipolar I disorder in adults: a phase 3, randomized controlled trial

Journal of affective disorders, 2017-10, Vol.221, p.275-282

2017

Volltextzugriff (PDF)

Measuring cognition and function in the preclinical stage of Alzheimer's disease

Alzheimer's & dementia : translational research & clinical interventions, 2018, Vol.4 (1), p.64-75

2018

Volltextzugriff (PDF)

O3‐09‐05: PLASMA TAU AND NEUROFILAMENT LIGHT CHAIN AS A PROGNOSTIC BIOMARKER OF DISEASE PROGRESSION IN EARLY ALZHEIMER'S DISEASE

Alzheimer's & dementia, 2018-07, Vol.14 (7S_Part_19)

2018

Volltextzugriff (PDF)

O3‐09‐05: PLASMA TAU AND NEUROFILAMENT LIGHT CHAIN AS A PROGNOSTIC BIOMARKER OF DISEASE PROGRESSION IN EARLY ALZHEIMER'S DISEASE

Alzheimer's & dementia, 2018-07, Vol.14 (7S_Part_19), p.P1038-P1039

2018

Volltextzugriff (PDF)

PLASMA TAU AND NEUROFILAMENT LIGHT CHAIN AS A PROGNOSTIC BIOMARKER OF DISEASE PROGRESSION IN EARLY ALZHEIMER’S DISEASE

Alzheimer's & dementia, 2018-07, Vol.14 (7), p.P1038-P1039

2018

Volltextzugriff (PDF)

ABBV-8E12, A HUMANIZED ANTI-TAU MONOCLONAL ANTIBODY, FOR TREATING EARLY ALZHEIMER’S DISEASE: UPDATED DESIGN AND BASELINE CHARACTERISTICS OF A PHASE 2 STUDY

Alzheimer's & dementia, 2019-07, Vol.15 (7), p.P251-P252

2019

Volltextzugriff (PDF)

P1‐050: ABBV‐8E12, A HUMANIZED ANTI‐TAU MONOCLONAL ANTIBODY, FOR TREATING EARLY ALZHEIMER'S DISEASE: UPDATED DESIGN AND BASELINE CHARACTERISTICS OF A PHASE 2 STUDY

Alzheimer's & dementia, 2019-07, Vol.15 (7S_Part_4), p.P251-P252

2019

Volltextzugriff (PDF)

Diagnosing and managing posttraumatic stress disorder

Cleveland Clinic journal of medicine, 2006-02, Vol.73 (2), p.121-122

2006

Volltextzugriff (PDF)

Sleep-related cortical arousals in adult subjects with negative polysomnography

Sleep & breathing, 2015-09, Vol.19 (3), p.989-996

2015

Volltextzugriff (PDF)

O1‐02‐06: ABBV‐8E12, A HUMANIZED ANTI‐TAU MONOCLONAL ANTIBODY FOR THE TREATMENT OF EARLY ALZHEIMER'S DISEASE: STUDY DESIGN AND BASELINE CHARACTERISTICS FOR A 96‐WEEK, MULTIPLE DOSE, RANDOMIZED, DOUBLE‐BLIND, PLACEBO‐CONTROLLED PHASE 2 STUDY

Alzheimer's & dementia, 2018-07, Vol.14 (7S_Part_4), p.P218-P219

2018

Volltextzugriff (PDF)

ABBV-8E12, A HUMANIZED ANTI-TAU MONOCLONAL ANTIBODY FOR THE TREATMENT OF EARLY ALZHEIMER’S DISEASE: STUDY DESIGN AND BASELINE CHARACTERISTICS FOR A 96-WEEK, MULTIPLE DOSE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY

Alzheimer's & dementia, 2018-07, Vol.14 (7), p.P218-P219

2018

Volltextzugriff (PDF)

FTS‐03‐04: TOMMORROW STUDY

Alzheimer's & dementia, 2014-07, Vol.10 (4S_Part_4), p.P247-P248

2014

Volltextzugriff (PDF)

1 – 25 von 55

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(47)
Mit Volltextzugriff
(53)

Publikationsform

Artikel
(55)

Sprache

Englisch
(55)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Humans
(19)
Life Sciences & Biomedicine
(17)
Science & Technology
(17)
Clinical Neurology
(8)
Neurology
(8)
Neurosciences & Neurology
(8)
Alzheimer's Disease
(6)
Psychiatry
(6)
Female
(5)
Treatment Outcome
(5)
Adult
(4)
Aged
(4)
Clinical Trials
(4)
General & Internal Medicine
(4)
Internal Medicine
(4)
Male
(4)
Antipsychotic Agents - Therapeutic Use
(3)
Diagnosis
(3)
Double-Blind Method
(3)
Medicine
(3)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson’s Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study

New applications of disease genetics and pharmacogenetics to drug development

Advancing combination therapy for Alzheimer's disease

Correction: Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson’s Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study

0895 Pharmacokinetics of pitolisant in breast milk and serum of healthy lactating women

Rapid Eye Movement Sleep Behavior Disorder

Rapid Eye Movement Sleep Behavior Disorder: A Review of the Literature and Update on Current Concepts

Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial

Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial

Portable Monitoring and the Diagnosis of Obstructive Sleep Apnea

Tilavonemab in early Alzheimer’s disease: results from a phase 2, randomized, double-blind study

Advances in treating insomnia

Innovative Approaches for Slowing Disease Progression in Parkinson's Disease: Takeaways from the 14th Annual International Society for Central Nervous System Clinical Trials and Methodology Scientific Meeting

Efficacy and safety of sublingual ramelteon as an adjunctive therapy in the maintenance treatment of bipolar I disorder in adults: a phase 3, randomized controlled trial

Measuring cognition and function in the preclinical stage of Alzheimer's disease

O3‐09‐05: PLASMA TAU AND NEUROFILAMENT LIGHT CHAIN AS A PROGNOSTIC BIOMARKER OF DISEASE PROGRESSION IN EARLY ALZHEIMER'S DISEASE

O3‐09‐05: PLASMA TAU AND NEUROFILAMENT LIGHT CHAIN AS A PROGNOSTIC BIOMARKER OF DISEASE PROGRESSION IN EARLY ALZHEIMER'S DISEASE

PLASMA TAU AND NEUROFILAMENT LIGHT CHAIN AS A PROGNOSTIC BIOMARKER OF DISEASE PROGRESSION IN EARLY ALZHEIMER’S DISEASE

ABBV-8E12, A HUMANIZED ANTI-TAU MONOCLONAL ANTIBODY, FOR TREATING EARLY ALZHEIMER’S DISEASE: UPDATED DESIGN AND BASELINE CHARACTERISTICS OF A PHASE 2 STUDY

P1‐050: ABBV‐8E12, A HUMANIZED ANTI‐TAU MONOCLONAL ANTIBODY, FOR TREATING EARLY ALZHEIMER'S DISEASE: UPDATED DESIGN AND BASELINE CHARACTERISTICS OF A PHASE 2 STUDY

Diagnosing and managing posttraumatic stress disorder

Sleep-related cortical arousals in adult subjects with negative polysomnography

O1‐02‐06: ABBV‐8E12, A HUMANIZED ANTI‐TAU MONOCLONAL ANTIBODY FOR THE TREATMENT OF EARLY ALZHEIMER'S DISEASE: STUDY DESIGN AND BASELINE CHARACTERISTICS FOR A 96‐WEEK, MULTIPLE DOSE, RANDOMIZED, DOUBLE‐BLIND, PLACEBO‐CONTROLLED PHASE 2 STUDY

ABBV-8E12, A HUMANIZED ANTI-TAU MONOCLONAL ANTIBODY FOR THE TREATMENT OF EARLY ALZHEIMER’S DISEASE: STUDY DESIGN AND BASELINE CHARACTERISTICS FOR A 96-WEEK, MULTIPLE DOSE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY

FTS‐03‐04: TOMMORROW STUDY

Suchergebnisse filtern